Semaglutide vs Tirzepatide
A comprehensive, data-driven comparison of Semaglutide (Ozempic) and Tirzepatide (Mounjaro). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Semaglutide Ozempic, Wegovy | Tirzepatide Mounjaro, Zepbound |
|---|---|---|
| FDA Status | FDA Approved | FDA Approved |
| Category | Weight Loss | Weight Loss |
| Primary Use | Type 2 diabetes and chronic weight management | Type 2 diabetes and chronic weight management |
| Weight Loss % | 15% | 22.5% |
| Monthly Cost | $1,000 - $1,400/mo | $1,100 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 2.4mg weekly (Wegovy dose) | 15mg weekly (max dose) |
| Frequency | Weekly | Weekly |
| Mechanism | GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow gastric emptying, and reduce appetite | Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Approved | Approved |
Key Differences
- 1Tirzepatide showed 22.5% average weight loss in trials compared to 15% for Semaglutide.
- 2Semaglutide is generally more affordable ($1,000 - $1,400/mo) compared to Tirzepatide ($1,100 - $1,500/mo).
Which Is Better For...
Tirzepatide
Maximum weight loss efficacy based on clinical trial data
Semaglutide
More budget-friendly option with lower monthly costs
Semaglutide
Fewer commonly reported side effects
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Semaglutide | $1,000 - $1,400/mo | FDA Approved | Novo Nordisk |
| Tirzepatide | $1,100 - $1,500/mo | FDA Approved | Eli Lilly |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Semaglutide works via GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow. Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. They differ in FDA approval status, efficacy data, and cost.
In clinical trials, Tirzepatide showed greater average weight loss (22.5%) compared to Semaglutide (15%). Individual results may vary.
Semaglutide typically costs $1,000 - $1,400/mo, while Tirzepatide costs $1,100 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Semaglutide is FDA-approved. Tirzepatide is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Semaglutide include Nausea, Diarrhea, Vomiting. Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. Clinical trials demonstrated an average weight loss of 15% over ...
View Full Semaglutide GuideTirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. It is the first medication to target both GIP and GLP-1 receptors simultane...
View Full Tirzepatide GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Semaglutide and Tirzepatide should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.